BioCentury on BioBusiness,
Tools & Techniques
Competing anti-angiogenic gene therapy
Monday, August 23, 1999
As EntreMed Inc. approaches the start of Phase I testing of its endostatin anti-angiogenic protein in the fall, the company is exploring alternatives to use of the protein itself. Thus, the company's gene therapy research collaboration with Cell Genesys Inc., announced last week, may avoid problems with manufacturing of the protein and the reproducibility of results with protein administration (see BioCentury, Feb. 16). On the other side of the coin, the partners will face gene therapy competition from Genetix Pharmaceuticals Inc.
ENMD and CEGE initially will evaluate CEGE's adenoviral and adeno-associated viral (AAV) gene delivery systems in combination with ENMD's genes for endostatin and Angiostatin anti-angiogenesis proteins in preclinical studies to treat cancer.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]